Nowadays, many patients with small-size primary require the neoadjuvant approach in breast cancer management, especially in triple-negative and HER-2 enriched variety; sentinel lymph node biopsy or axillary dissection is a choice for axillary staging in breast cancer, but axillary dissection is still the standard treatment in cases of biopsy-proven node-positive breast cancer in upfront settings. This evidence concerns the gene ERBB2 and breast carcinoma.